Explores novel TEAD inhibitors, highlighting a new method for drug discovery.
-deficient xenografts. Collectively, this work integrates structure-based design with CuAAC-enabled parallel synthesis and in situ screening, enabling rapid discovery of TEAD inhibitors and offering a generalizable route for targets with structurally defined pockets.
No takes yet. Share an insight, caveat, or question.
Miao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: